Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases
ESMO
European Society for Medical Oncology (ESMO)
July 4, 2025
,
Schlechter, et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Monitoring botensilimab- and balstilimab-induced T cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer
ASCO
American Society for Clinical Oncology (ASCO)
May 31, 2025
,
Rasschaert et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma
AACR
American Association for Cancer Research (AACR)
May 12, 2025
,
El-Khoueiry, et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study
AACR
American Association for Cancer Research (AACR)
April 29, 2025
,
Chalabi et al.